News

ANNOUNCEMENT OF CARDINAL HEALTH’S CORDIS BUSINESS SALE

The completion of the sale of Cardinal Health’s Cordis business to Hellman & Friedman has been publicly announced. The sale price is approximately $1 billion and includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts. Cardinal Health plans to release its fourth-quarter and year-end financial results for its fiscal year 2021 on August 5 prior to the opening of trading on the New York Stock Exchange.

Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. Cardinal Health is 50 years in business, operates in more than 40 countries and has approximately 48,000 employees globally.

Hellman & Friedman is a global private equity firm with a distinctive investment approach focused on large-scale equity investments in high quality growth businesses. The firm is currently investing its tenth fund, with over $24 billion of committed capital, and has over $80 billion in assets under management and committed capital.